AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01503463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home telemonitoring of patients with CHF
Description: Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified.
Study NCT01735786 — intervention group
Intervention type: DEVICE
Intervention: EndoClot
Description: EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
Study NCT03538925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAC Generative Language Intervention
Description: Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention
Study NCT03538925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care / Business as Usual
Description: Parent/Caregiver AAC App Operational Training
Study NCT03538925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care / Business as Usual
Description: Parent/Caregiver AAC App Operational Training
Study NCT01909739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atrovastatin
Description: Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
Study NCT01909739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
Study NCT00679250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine
Description: 5 mg once nightly before visit
Study NCT00679250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to levocetirizine
Description: 1 tablet once nightly before visit
Study NCT02900482 — intervention group
Intervention type: OTHER
Intervention: Sampling saliva
Study NCT04335838 — intervention group
Intervention type: OTHER
Intervention: retrospective analysis
Description: The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
Study NCT01649791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT01649791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT00570167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip resurfacacing
Description: Hip resurfacing with cementless acetabular cup and cemented femoral head
Study NCT00570167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless total hip arthroplasty with m-o-m bearings
Description: Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
Study NCT01649791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node biopsy
Description: Correlative study
Study NCT01649791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative study
Study NCT01649791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study NCT01649791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative study
Study NCT04257279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ExcelsiusGPS™
Description: The ExcelsiusGPS™ is a Robotic Positioning System that includes a computer controlled robotic arm, hardware, and software that enables real time surgical navigation and robotic guidance using radiological patient images (pre-operative CT, intra-operative CT and fluoroscopy), using a dynamic reference base and positioning camera.
Study NCT03843827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
Study NCT03843827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I gel Airway
Description: I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
Study NCT01066403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergolide
Description: 0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group.
Study NCT04363515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support network counseling intervention
Description: Pilot social support counseling intervention for kidney transplant candidates along with their social support networks
Study NCT02276326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3 sachets
Description: 4 sachets a day for 4 months
Study NCT03459482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Elimination Diet
Description: Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
Study NCT03459482 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Food Elimination Diet
Description: Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
Study NCT03801083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
Study NCT03871998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin barrier protection in the first 2 months of life
Description: Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
Study NCT01719289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROGRAVIDA
Description: Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
Study NCT00303303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)
Description: Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
Study NCT01839838 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Study NCT00303303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)
Description: Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
Study NCT00303303 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
Study NCT00693589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid, vitamin B12 and B6 and rosuvastatin
Description: Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
Study NCT02700022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/lixisenatide fixed ratio combination
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide extended-release
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dulaglutide
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Description: Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
Study NCT02787551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Description: Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
Study NCT02276365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Study NCT02276365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT03014492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q Collar
Description: Collar designed to mitigate slosh in the brain
Study NCT03509831 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: INT-2150
Description: 1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg
Study NCT03509831 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irsogladine maleate 2 mg+Nizatidine 150 mg
Description: 1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150
Study NCT00591266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil and amlodipine
Description: Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00591266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil and amlodipine
Description: Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00591266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00537875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Description: Capsule, 1000 mg, BID, 3 days
Study NCT00537875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, 1000 mg, BID, 3 days
Study NCT01135212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan 60mg
Description: Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
Study NCT01135212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan 120mg
Description: Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
Study NCT01135212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
Study NCT03825744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine+Standard Therapy
Description: once daily
Study NCT03825744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+Standard Therapy
Description: once daily
Study NCT03106025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
Study NCT03106025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
Study NCT03106025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmology Assessment
Description: Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
Study NCT03106025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmology Assessment
Description: Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
Study NCT03661190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Grammatical Reasoning
Description: START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
Study NCT03661190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Card Pairs
Description: A basic picture-matching task.
Study NCT00715923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified consent form
Description: modified consent form used
Study NCT00715923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard consent form
Description: standard consent form used
Study NCT04408131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: virological test
Study NCT04408131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: serological test
Study NCT01268891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily; tablet; orally; 18 weeks
Study NCT01268891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilect®
Description: 1 mg daily; tablet; orally; 18 weeks
Study NCT01164683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Description: Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
Study NCT01164683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
Study NCT03530800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
Study NCT03530800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 10 weeks
Study NCT01924624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
Study NCT01924624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
Study NCT02589379 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreatic Resection
Description: Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
Study NCT01157234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of \< 140/ 90.
Study NCT01157234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure \< 140/90.
Study NCT02120612 — intervention group
Intervention type: OTHER
Intervention: Naloxone Education Intervention
Description: The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders.
Study NCT02034032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx SD
Description: stem cell treatment
Study NCT02034032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: exercise therapy control
Study NCT00973674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin IV
Description: One time dose of Premarin IV
Study NCT00973674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time dose of Placebo
Study NCT03521427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive bimanual therapy
Description: Ninety hours of intensive bimanual therapy
Study NCT03521427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive neurodevelopmental therapy
Description: Ninety hours of intensive neurodevelopmental therapy
Study NCT04619459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Description: Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
Study NCT00815399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15-45 mg/die
Study NCT00815399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500-2000 mg/die